Neurocrine Biosciences Inc (NBIX)vsViatris Inc (VTRS)
NBIX
Neurocrine Biosciences Inc
$163.41
+2.25%
HEALTHCARE · Cap: $16.77B
VTRS
Viatris Inc
$16.43
+0.86%
HEALTHCARE · Cap: $20.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 332% more annual revenue ($14.56B vs $3.37B). NBIX leads profitability with a 20.9% profit margin vs -2.0%. NBIX appears more attractively valued with a PEG of 0.47. NBIX earns a higher WallStSmart Score of 81/100 (A-).
NBIX
Exceptional Buy81
out of 100
Grade: A-
VTRS
Hold48
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Revenue surging 39.5% year-over-year
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 22.7%
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, Altman Z-Score. Profitability is solid with margins at 20.9% and operating margin at 22.7%. Revenue growth of 39.5% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.12 suggests the stock is reasonably priced for its growth.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
NBIX profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
NBIX is growing revenue faster at 39.5% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (81/100 vs 48/100), backed by strong 20.9% margins and 39.5% revenue growth. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?